Medications for Cholesterol That Are Not Statins

Several classes of non-statin medications can lower cholesterol and reduce cardiovascular risk, and the options have expanded considerably over the past decade. While statins remain the default first-line treatment, drugs like ezetimibe, PCSK9 inhibitors, bempedoic acid, and others work through entirely different biological pathways and have their own track records in large clinical trials. Some are add-ons for people already on statins who need deeper LDL reduction, while others serve as alternatives for the sizable number of patients who cannot tolerate statins at all.

Why Non-Statin Options Matter

Statins are effective, but they do not work for everyone. Muscle-related side effects are one of the most commonly cited reasons people stop taking them, though the picture is complicated: some of those muscle symptoms are genuine drug effects, while others appear to be driven by the nocebo effect, where a person’s expectation of harm produces real discomfort.¹ Regardless of the cause, if someone stops taking their statin, their cardiovascular risk stays elevated. Beyond intolerance, many patients on the maximum statin dose they can handle still do not hit their LDL cholesterol targets. Current guidelines recognize ezetimibe, bempedoic acid, and the various PCSK9-targeting therapies as options to layer on top of whatever statin dose a person tolerates, or to use independently when statins are off the table entirely.²

Ezetimibe

Ezetimibe was one of the first major non-statin cholesterol drugs and remains one of the most widely prescribed. It works in the small intestine, blocking a protein called NPC1L1 that is responsible for absorbing cholesterol from food and bile.³ Structural studies have shown that ezetimibe physically plugs the tunnel that NPC1L1 uses to move cholesterol, rather than competing with cholesterol for the same binding site.⁴ The net result is less cholesterol entering your bloodstream from the gut, which nudges LDL levels down by a modest but meaningful amount on its own, and further when added to a statin.

The cardiovascular payoff of that additional LDL lowering was established in the IMPROVE-IT trial, which followed over 18,000 patients after an acute coronary event. Adding ezetimibe to simvastatin reduced cardiovascular events compared with simvastatin alone. Total cardiovascular events dropped by about 9%, with especially strong reductions in heart attacks and strokes.⁵ The absolute difference was modest, with about two fewer major events per hundred patients over seven years, but for a cheap, well-tolerated pill, that adds up across a large population.⁶ Ezetimibe is now generic, costs very little, and is often the first drug a doctor reaches for when a statin alone is not enough.

PCSK9 Inhibitors

PCSK9 is a protein your liver makes that attaches to LDL receptors on the surface of liver cells and flags them for destruction. Fewer LDL receptors means less LDL gets pulled out of your blood, so cholesterol levels rise.⁷ Blocking PCSK9 keeps those receptors working longer and clears LDL much more aggressively. Two monoclonal antibody drugs, alirocumab (Praluent) and evolocumab (Repatha), do exactly this. They are given as injections, typically every two to four weeks.

The evidence behind these drugs is strong. Two major outcome trials, FOURIER for evolocumab and ODYSSEY OUTCOMES for alirocumab, both showed significant reductions in major adverse cardiovascular events on top of statin therapy.⁸ In ODYSSEY OUTCOMES, patients who received alirocumab after an acute coronary event had a roughly 15% lower rate of the composite cardiovascular endpoint compared with placebo.⁹ These drugs can cut LDL by 50 to 60% beyond what statins achieve, which makes them especially valuable for people with very high baseline levels or established heart disease who need aggressive lowering.

Inclisiran

Inclisiran takes a different route to the same destination. Instead of blocking the PCSK9 protein after it is made, inclisiran uses a small interfering RNA molecule to prevent the liver from producing PCSK9 in the first place.¹⁰ The practical advantage is dosing frequency: inclisiran is given just twice a year after an initial loading phase, compared with every two to four weeks for the monoclonal antibodies. Clinical trials show it lowers LDL by roughly 50% when added to maximally tolerated statins.¹¹ That twice-yearly schedule is appealing for adherence: you get the injection at a doctor’s visit and do not have to remember anything at home. The trade-off is that cardiovascular outcome data for inclisiran are still maturing. Large trials are underway, and while the LDL-lowering magnitude is comparable to the monoclonal antibodies, the long-term event-reduction proof is not yet as extensive.

Bempedoic Acid

Bempedoic acid (Nexletol) is an oral pill that inhibits an enzyme called ATP-citrate lyase in the liver, one step upstream of the enzyme that statins block.¹² The result is similar: the liver compensates by pulling more LDL cholesterol out of the blood. A key feature is that bempedoic acid is a prodrug activated by an enzyme found mainly in the liver, not in muscle tissue. Because it is not active in skeletal muscle, it largely avoids the muscle-related side effects that drive statin intolerance.

The CLEAR Outcomes trial tested bempedoic acid in over 13,000 patients who were unable or unwilling to take statins. The drug reduced the primary composite cardiovascular endpoint by about 13% compared with placebo, and heart attacks specifically dropped by nearly a quarter.¹³ A prespecified analysis of all cardiovascular events (not just first events) showed an even more consistent pattern, with total heart attacks reduced by about 31% and coronary revascularization procedures down by about 22%.¹⁴ For someone who genuinely cannot take a statin, bempedoic acid is one of the few oral non-statin drugs proven to lower cardiovascular events in its own dedicated outcome trial. It does raise uric acid levels, so people with a history of gout need to be monitored.

Bile Acid Sequestrants

Bile acid sequestrants (cholestyramine, colestipol, colesevelam) are among the oldest cholesterol-lowering drugs, predating statins. They work by binding to bile acids in the intestine, preventing their normal recycling back to the liver. This forces the liver to pull cholesterol from the blood to make new bile acids, lowering LDL in the process. The drugs are effective at their job, but their side-effect profile has limited their popularity. Because they disrupt the normal bile acid pool in the gut, they commonly cause constipation, bloating, or diarrhea.¹⁵ They can also interfere with the absorption of other medications, so timing of doses matters. Despite these drawbacks, bile acid sequestrants still have a role for specific patients: they are safe in pregnancy (unlike most other lipid drugs), they can be helpful for people who need modest additional LDL lowering, and colesevelam has a secondary benefit of improving blood sugar in type 2 diabetes.

Fibrates

Fibrates like fenofibrate and gemfibrozil primarily target triglycerides rather than LDL cholesterol. They activate a receptor in the cell nucleus called PPAR-alpha, which increases the breakdown of triglyceride-rich particles and reduces the liver’s production of the lipoproteins that carry triglycerides.¹⁶ They also modestly raise HDL (“good”) cholesterol. However, unlike statins, their cardiovascular benefit appears to be concentrated in a specific group of patients: those with high triglycerides and low HDL. The large ACCORD-Lipid trial did not show a general benefit of adding fenofibrate to statin therapy in people with type 2 diabetes, but subgroup analysis suggested meaningful benefit in patients who had both high triglycerides (above 200 mg/dL) and low HDL (below about 35 to 40 mg/dL).¹⁷ If your primary problem is elevated LDL and your triglycerides are normal, fibrates are not the right tool.

Icosapent Ethyl

Icosapent ethyl (Vascepa) is a prescription-grade, highly purified form of the omega-3 fatty acid EPA. It is distinct from the over-the-counter fish oil supplements that most people think of when they hear “omega-3,” both in purity and in clinical evidence. The REDUCE-IT trial enrolled over 8,000 statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors. Those randomized to icosapent ethyl saw a 25% reduction in the primary composite cardiovascular endpoint compared with placebo, including lower rates of cardiovascular death.¹⁸ The benefit appears to go beyond simple triglyceride reduction. Real-world data suggest that icosapent ethyl improves the overall profile of atherogenic lipoproteins and reduces inflammatory biomarkers.¹⁹

An important nuance: mixed omega-3 supplements containing both EPA and DHA have generally failed to show the same cardiovascular benefit in trials. The specificity of icosapent ethyl to EPA alone seems to matter, and store-bought fish oil capsules are not a substitute. There has also been debate about the mineral oil placebo used in REDUCE-IT, which may have slightly raised LDL in the control group, potentially exaggerating the apparent benefit. That controversy has not been fully resolved, but regulatory agencies in several countries approved icosapent ethyl for cardiovascular risk reduction on the strength of the overall data.

The Niacin Story

Niacin (vitamin B3) was one of the earliest drugs used to treat cholesterol, and it has an impressively broad effect on lipid numbers: it raises HDL, lowers triglycerides, and modestly lowers LDL. For decades, there was genuine hope that niacin’s HDL-raising ability would translate into fewer heart attacks and strokes. That hope was dashed by two large trials. The AIM-HIGH trial found that adding niacin to statin therapy did not reduce cardiovascular events despite improving HDL and triglyceride levels over three years of follow-up.²⁰ The HPS2-THRIVE trial, testing extended-release niacin combined with an anti-flushing agent, was stopped early for lack of benefit. In HPS2-THRIVE, niacin improved the lipid panel on paper but did not reduce the primary cardiovascular endpoint at all, and the event rates were virtually identical between the niacin and placebo groups.²¹ Niacin also comes with unpleasant side effects, including flushing, itching, and elevated blood sugar. As a result, most guidelines no longer recommend niacin as a routine add-on to statins. It is a cautionary example of how improving a lab number does not always translate into fewer real events.

Drugs for Severe Familial Hypercholesterolemia

Most of the drugs discussed so far work, at least in part, by increasing the number or activity of LDL receptors on liver cells. That strategy has a built-in limitation: it does not help patients who have few or no working LDL receptors due to genetic mutations. People with homozygous familial hypercholesterolemia (HoFH) inherit defective LDL receptor genes from both parents, and their cholesterol levels can be extraordinarily high from childhood. Patients with the most severe “null-null” mutations respond poorly, if at all, to statins and PCSK9 inhibitors.²²

Two drugs address this gap by using entirely LDL receptor-independent mechanisms. Evinacumab (Evkeeza) is a monoclonal antibody that blocks a protein called ANGPTL3, which normally puts the brakes on enzymes that clear fats from the blood. By releasing those brakes, evinacumab lowers LDL through a pathway that does not require the LDL receptor at all.²³ In a trial of HoFH patients, evinacumab reduced LDL cholesterol by roughly 47% in those with null-null mutations, a population where most other drugs barely move the needle.²⁴

Lomitapide (Juxtapid) takes yet another approach: it inhibits microsomal triglyceride transfer protein (MTP), which the liver needs to assemble and secrete the lipoproteins that carry cholesterol. Blocking MTP reduces the production of these particles, again independently of LDL receptors.²⁵ Lomitapide is effective but requires a strict low-fat diet and regular liver monitoring, since fat that the liver cannot export accumulates there. Both evinacumab and lomitapide are approved specifically for HoFH and are not used in the general population.

Emerging Therapies Targeting Lipoprotein(a)

Lipoprotein(a), often abbreviated Lp(a), is a genetically determined type of LDL-like particle that is an independent risk factor for cardiovascular disease. Until recently, no drug could meaningfully lower Lp(a) levels. That is changing. Olpasiran, a small interfering RNA, has shown dramatic reductions in Lp(a) in early trials. In a dose-ranging study, higher doses of olpasiran lowered Lp(a) by essentially 100% from baseline, with the effect lasting months after a single injection.²⁶ It works by blocking the liver’s production of apolipoprotein(a), the protein component unique to Lp(a).²⁷

Another drug in this space is pelacarsen, an antisense oligonucleotide that also targets apolipoprotein(a) production. A phase 2b study of pelacarsen showed Lp(a) reductions of 80% or more with a favorable safety profile.²⁸ The critical question for both drugs is whether lowering Lp(a) actually prevents heart attacks and strokes, or whether it is another niacin-like scenario where the lab number improves but outcomes do not follow. Large cardiovascular outcome trials for both olpasiran and pelacarsen are ongoing, and results over the next few years will determine whether these drugs become standard treatments for the substantial minority of people with elevated Lp(a).

Cost and Access Barriers

The newer injectable therapies, especially the PCSK9 inhibitors and inclisiran, are far more expensive than generic statins or ezetimibe. This creates real-world friction. A scoping review of barriers to injectable lipid-lowering therapy found that initial insurance denial rates can reach 80 to 90%, with complex prior authorization processes creating frustration for patients and doctors alike.²⁹ Even when coverage is obtained, financial strain can lead to treatment interruptions or discontinuation. The price of PCSK9 monoclonal antibodies has come down from their initial launch costs after negotiation and competition, but they still represent a significant expense compared with generic pills.

Bempedoic acid and ezetimibe, by contrast, are both available as relatively affordable oral medications. For many patients, the practical treatment ladder starts with maximally tolerated statins, then adds ezetimibe, then bempedoic acid, and only escalates to injectable PCSK9 inhibitors or inclisiran if targets are not met. Insurance typically requires documentation that cheaper options were tried first. This stepwise approach makes clinical sense, but it also means that the patients who need the most powerful drugs often face the longest bureaucratic path to get them.

Lipid Lowering in Kidney Disease

People with chronic kidney disease have distinct patterns of dyslipidemia, and what works in the general population does not always translate cleanly to this group. Current guidelines generally recommend statins for patients with non-dialysis-dependent chronic kidney disease, but the evidence for non-statin lipid therapies in this population is thin. Triglyceride-lowering drugs like fibrates and niacin can raise HDL in people without kidney disease, but those effects may not hold the same meaning for patients with kidney disease, given their different underlying lipid metabolism. High-quality clinical trials of these drugs specifically in kidney disease patients are still lacking, which leaves doctors extrapolating from data that may not fully apply. For now, statin therapy remains the evidence-backed mainstay in this population, and the role of newer agents is being explored cautiously.